Abstract
Well-established evidence links extracellular nucleotides to numerous vascular pathologies, including restenosis associated with angioplasty, atherosclerosis and transplant arteriosclerosis. Through activation of purinergic P2 receptors, extracellular nucleotides contribute to the pathogenesis of occlusive vascular diseases by mediating thrombosis, and vascular smooth muscle proliferation and migration. Therefore, there is a growing interest in the enzymes that hydrolyze nucleotides for their capability to modulate nucleotide-triggered pathologies. In this review, we present the current data addressing the therapeutic potential of nucleoside triphosphate diphosphohydrolases (NTPDases) to prevent intimal hyperplasia and treat vascular intimal disease. In addition, we discuss the mechanisms by which NTPDases exert protective effects in vascular function.
Keywords: Endothelium, stenosis, NTPDase, purinergic P2 receptors, extracellular nucleotides, vascular function, transplant arteriosclerosis, mediating thrombosis, nucleotide-triggered pathologies, endovascular approaches, endothelial nitric oxide synthase, balloon angioplasty, stimulate fibroblast proliferation, adenylate cyclase activity, development of intimal thickening
Current Pharmaceutical Biotechnology
Title: Targeting Stenosis with Nucleotide-Hydrolyzing Enzymes
Volume: 12 Issue: 11
Author(s): Elzbieta Kaczmarek and Katarzyna Koziak
Affiliation:
Keywords: Endothelium, stenosis, NTPDase, purinergic P2 receptors, extracellular nucleotides, vascular function, transplant arteriosclerosis, mediating thrombosis, nucleotide-triggered pathologies, endovascular approaches, endothelial nitric oxide synthase, balloon angioplasty, stimulate fibroblast proliferation, adenylate cyclase activity, development of intimal thickening
Abstract: Well-established evidence links extracellular nucleotides to numerous vascular pathologies, including restenosis associated with angioplasty, atherosclerosis and transplant arteriosclerosis. Through activation of purinergic P2 receptors, extracellular nucleotides contribute to the pathogenesis of occlusive vascular diseases by mediating thrombosis, and vascular smooth muscle proliferation and migration. Therefore, there is a growing interest in the enzymes that hydrolyze nucleotides for their capability to modulate nucleotide-triggered pathologies. In this review, we present the current data addressing the therapeutic potential of nucleoside triphosphate diphosphohydrolases (NTPDases) to prevent intimal hyperplasia and treat vascular intimal disease. In addition, we discuss the mechanisms by which NTPDases exert protective effects in vascular function.
Export Options
About this article
Cite this article as:
Kaczmarek Elzbieta and Koziak Katarzyna, Targeting Stenosis with Nucleotide-Hydrolyzing Enzymes, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798377111
DOI https://dx.doi.org/10.2174/138920111798377111 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardioprotective Role of <i>Theobroma cacao</i> against Isoproterenol-Induced
Acute Myocardial Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug Targeting of Estrogen Receptor Signaling in the Cardiovascular System: Preclinical and Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Letters in Drug Design & Discovery Diet and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: Plasminogen Activator Inhibitor-1 (Guest Editor: Daniel A. Lawrence)]
Current Drug Targets Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review
Current Drug Metabolism Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?
Mini-Reviews in Medicinal Chemistry Clinical Applications of Transcranial Doppler Sonography
Reviews on Recent Clinical Trials Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia
Current Pharmaceutical Design Systematic Review of Public Education and Policy for Stroke Prevention
Current Drug Targets Forceps: Still an Option?
Current Women`s Health Reviews Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents
Current Pharmaceutical Design Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Targeting the Role of Lipoprotein (a) in Stroke
Cardiovascular & Hematological Disorders-Drug Targets Oxidized-LDL and Paraoxonase-1 As Biomarkers of Coronary Artery Disease in Patients with Sleep-Disordered Breathing
Current Medicinal Chemistry Spectral Methods of Characterizing the Conformational Changes of Glycated Goat Liver Cystatin
Current Proteomics Impact of the Renin-Angiotensin-Aldosterone-System on Cardiovascular and Renal Complications in Diabetes Mellitus
Current Vascular Pharmacology Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry